NDA 020191 · Novartis
Alomide
Lodoxamide Tromethamine · Ophthalmic
NovelOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 26, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Sep 23, 1993
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 23, 1993 Original approval · Type 1 - New Molecular Entity
1 products under this application
- ALOMIDE · LODOXAMIDE TROMETHAMINE EQ 0.1% BASE · SOLUTION/DROPS, OPHTHALMIC · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Lodoxamide Tromethamine" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Alomide (Lodoxamide Tromethamine)
2024 spending
$92K
Beneficiaries
182
374 claims
Per beneficiary
$505
$19.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $64,109 |
| 2024 | $91,853 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effect of lodoxamide tromethamine on the immediate asthmatic response to allergen provocation.
Ollier S, Graham VA, Bentley S, et al. · Clin Allergy 1982 · Clinical Trial, Randomized Controlled Trial
- Efficacy of lodoxamide eye drops on tear fluid cytology of patients with vernal conjunctivitis.
Oguz H, Bitiren M, Aslan OS, et al. · Acta Med Okayama 1999 · Clinical Trial, Randomized Controlled Trial
- [An efficacy study of lodoxamide treatment in allergic eye lesions].
Giuri S, Munteanu GH · Oftalmologia 2000 · Clinical Trial, English Abstract
- Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study.
Fahy GT, Easty DL, Collum LM, et al. · Eur J Ophthalmol 1992 · Clinical Trial, Comparative Study
- Contrast of the effect of alomide and sodium cromoglycate in the treatment of allergic eye diseases.
Zhang W, Lin Z · Yan Ke Xue Bao 2000 · Clinical Trial, Comparative Study
- Lodoxamide treatment of allergic conjunctivitis.
Cerqueti PM, Ricca V, Tosca MA, et al. · Int Arch Allergy Immunol 1994 · Clinical Trial, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.